Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

84.18
-0.5100-0.60%
Post-market: 83.15-1.0300-1.22%17:00 EDT
Volume:934.03K
Turnover:79.06M
Market Cap:5.38B
PE:-78.87
High:86.10
Open:84.01
Low:83.60
Close:84.69
Loading ...

RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

Zacks
·
24 Feb

Cautious Optimism: Hold Rating Given to Blueprint Medicines Amid Financial Performance Concerns and Slower Ayvakit Growth Projections

TIPRANKS
·
17 Feb

Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
·
15 Feb

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Zacks
·
15 Feb

Blueprint Medicines Price Target Maintained With a $125.00/Share by JMP Securities

Dow Jones
·
14 Feb

Morgan Stanley Sticks to Their Hold Rating for Blueprint Medicines (BPMC)

TIPRANKS
·
14 Feb

Blueprint Medicines Corporation (NASDAQ:BPMC) Is Expected To Breakeven In The Near Future

Simply Wall St.
·
14 Feb

Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...

GuruFocus.com
·
14 Feb

Q4 2024 Blueprint Medicines Corp Earnings Call

Thomson Reuters StreetEvents
·
14 Feb

Blueprint Medicines: Positive Earnings Call Highlights Growth

TIPRANKS
·
14 Feb

Strong Market Position and Growth Potential Drive Buy Rating for Blueprint Medicines

TIPRANKS
·
14 Feb

Blueprint Medicines should be bought on any weakness, says Stifel

TIPRANKS
·
14 Feb

Optimistic Growth Potential and Market Expansion Justify Buy Recommendation for Blueprint Medicines

TIPRANKS
·
14 Feb

Blueprint Medicines selloff to be short-lived, says Oppenheimer

TIPRANKS
·
14 Feb

Wedbush Adjusts Price Target on Blueprint Medicines to $128 From $124, Maintains Outperform Rating

MT Newswires Live
·
13 Feb

Blueprint Medicines Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Stock Track | Blueprint Medicines Plummets 8.27% as Q4 Earnings Miss Overshadows Revenue Beat

Stock Track
·
13 Feb

Blueprint Medicines Price Target Maintained With a $133.00/Share by Needham

Dow Jones
·
13 Feb

Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
13 Feb

Blueprint Medicines Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
13 Feb